Former General Secretary of the CPSUFormer President of the Soviet UnionSecretariate (1985–90)Presidency (1990–91)Foreign policyPost-presidencyGreen Cross International is an environmentalist organisation headquartered in Geneva, Switzerland, founded by former Soviet leader Mikhail Gorbachev in 1993. Today there are member organisations in 30 countries. Its primary mission is to "respond to the combined challenges of security, poverty and environmental degradation to ensure a sustainable and secure future".
The Media & Entertainment (M&E) sector is undergoing a profound technological and structural transformation. Audiences are shifting towards on-demand, immersive, and interactive content; AI and generative media are becoming integral to production and distribution; and live events increasingly rely on digital augmentation. Against this backdrop, 6G technologies—supported by innovations in AI, edge computing, non-terrestrial networks, sensing, and distributed intelligence—are poised to redefine how media is created, delivered, and experienced.Within this evolving landscape, the Smart Networks and Services Joint Undertaking (SNS JU) plays a central role in shaping Europe’s technological leadership. Through 22 dedicated projects and 46 use cases, SNS JU is developing and validating the network capabilities, architectural enablers, and experimental platforms that will make 6G-enabled M&E applications technically feasible, economically sustainable, and societally acceptable.SNS JU projects collectively address the stringent performance needs of next-generation M&E services—ultra-high bandwidth, sub-millisecond latency, massive device density, distributed compute, precise positioning, integrated sensing, and advanced security.This white paper provides an extensive analysis of the current status of the M&E sector, based on SNS JU experts and an extensive research of the industrial M&E domain, and the promising technologies and features of 6G that stand to bring M&E services to the 2030s.Despite strong progress from SNS JU projects, significant challenges remain for large-scale 6G adoption in the M&E sector. Achieving the advanced infrastructure required for sub-THz communications, distributed MIMO, and edge-centric architectures demands high investment, while uplink limitations still constrain volumetric capture and remote production. Immersive and metaverse applications also heighten privacy and security risks due to their dependence on sensitive biometric and behavioural data. Interoperability gaps between devices, platforms, and formats threaten ecosystem fragmentation, and today’s end-user devices—limited in battery, processing, display, and cost—continue to restrict the quality of immersive experiences.At the same time, 6G offers major opportunities to transform M&E through hybrid digital-physical events, immersive broadcasting, holographic telepresence, and cloud-native collaborative production. Ultra-high bandwidth, low latency, and distributed AI will support richer, more interactive content and personalized user experiences, while metaverse applications expand into culture, education, tourism, and industry. Sustainability will become a central value driver as carbon-aware streaming and energy-efficient delivery influence both operators and consumers. Early 6G adoption is expected in premium immersive services and professional production environments, broadening as devices mature and standards solidify. With continued investment, coordinated regulation, and leadership in R&I, Europe is well positioned to shape the global future of 6G-enabled media.
The Gravitational Reference Advanced Technology Test In Space (GRATTIS) mission will demonstrate the end-to-end functionality and sensitivity performance of the Simplified Gravitational Reference Sensor (S-GRS), an ultra-precise inertial sensor for future Earth geodesy missions. These sensors are used to measure or compensate for all non-gravitational accelerations of the host spacecraft so that they can be removed in the data analysis to recover spacecraft motion due to Earth's gravity field, the main science observable. The S-GRS concept is a simplified version of the flight-proven LISA Pathfinder GRS. It consists of a free-falling cubic test mass inside an electrode housing that senses the position and orientation of the test mass and electrostatically applies forces and torques to it to keep it centered at a nanometer-level. The improved performance of the S-GRS is enabled by removing the small grounding wire used in the GRACE accelerometers, which limits its performance, and replacing it with a UV LED-based charge management system, increasing the mass of the sensor's TM, and increasing the gap between the TM and its electrode housing. GRATTIS will fly two identical S-GRS mounted next to one another at the center of mass of a 160 kg ESPA-class commercial microsatellite with a planned launch in 2027. The six-axis acceleration measurement capability of the S-GRS allows precision measurement of the spacecraft drag-induced translational acceleration, as well as the residual angular acceleration of the nominally inertially-pointed bus. By combining the outputs of each sensor and with the known relative position of the two TMs, we can recover the acceleration sensitivity (noise floor) of the S-GRS.
Adenoid cystic carcinoma (ACC) is predominantly a malignant neoplasm of the salivary glands but rarely can develop in the lungs as a primary tumor from bronchial glands, accounting for only 0.04%– 0.2% of all pulmonary malignancies. Its slow growth, infiltrative nature, and nonspecific respiratory symptoms often mimic other conditions, creating considerable diagnostic and therapeutic challenges. We report a case of a 50-year-old male radiotechnologist presented with recurrent hemoptysis and unintentional weight loss. Despite a normal chest X-ray, HRCT revealed a 4 × 3.1 cm soft tissue lesion completely obstructing the right principal bronchus with collapse of the right lower lobe. Pathological evaluation of bronchoscopic samples confirmed adenoid cystic carcinoma, necessitating a right lower bilobectomy. Subsequent histopathological examination revealed an intermediategrade ACC with classic cribriform patterns, without lymphovascular and perineural invasion, and involvement of the middle lobe bronchial margin (stage pT1b pNx pMx). Margin positivity raised concerns for potential recurrence, highlighting the need for meticulous follow-up and consideration of adjuvant therapy. This case emphasizes the importance of histopathological confirmation, margin assessment, and long-term surveillance in managing this rare pulmonary malignancy. Journal of Green Life Med. Col. 2025; 10(2): 62- 65
Adoptive immunotherapy with engineered T cells, especially chimeric antigen receptor (CAR) T cells, has revolutionized the treatment of leukemia, lymphoma, and multiple myeloma. However, the high production costs of CAR-T therapy severely limit patient access. To address this challenge, we developed T-pureTM, a proprietary bispecific antibody cocktail for isolating T cells from human blood through negative selection. The Bi-specific antibody cocktail selectively links red blood cells (RBCs) to key marker antigens on non-target cells, such as B cell, NK cell, Monocytes, and granulocytes, allowing easy and cost-effective separation using Ficoll density gradient centrifugation. By isolating T cells without engaging their surface receptors, this approach avoids inadvertent activation of isolated T cells, while also preserving cell types like γδ T cells, which show promise for their anti-tumor potential. Additionally, the depletion process efficiently removes CD19-positive cancer cells and can be tailored to eliminate T cell subpopulations like T regulatory (T-reg) cells that could compromise CAR-T efficacy in clinical application. This versatile antibody cocktail can also be adapted to isolate other cell types, such as NK cells, B cells, and monocytes for various biomedical applications. Designed for cost-effective clinical manufacturing, our GMP grade T-pure reagents are commercially available to academic and industry partners for preclinical and clinical applications. This work highlights the ongoing innovation in CAR-T manufacturing and the potential for optimizing cell selection protocols to enhance efficacy and lower the cost of cell therapies. Ying Xiong, Yanping Xie, Ann Wang, Victor Bass, Matt Addington-hall, Oxana Slessareva, Yang Liu, Tony Luo, Ibeawuchi Oparaocha, Kathy Schonely, Kara Anlauf, Megan Forrest, Jacqueline Schaeffer, Shashi Koduru, Andrew Worden, Mike Kadan, Boro Dropulic, Zhongyu Zhu. T-PureTM: A bispecific antibody cocktail for T cell isolation from human blood, enabling simple and affordable point-of-care CAR-T manufacturing [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 6095.
Abstract not available Journal of Green Life Med. Col. 2025; 10(2): 39-40
